

Houke M Klomp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9574868/publications.pdf>

Version: 2024-02-01

48
papers

1,789
citations

279798

23
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

2642
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. <i>JAMA Oncology</i> , 2021, 7, e205865.	7.1	45
2	Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2020, 150, 209-215.	2.0	2
3	Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands. <i>Acta Oncologica</i> , 2020, 59, 748-752.	1.8	2
4	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1569-1576.	1.1	206
5	Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. <i>Lung Cancer</i> , 2017, 112, 134-139.	2.0	33
6	Tumor heterogeneity on 18F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. <i>Journal of Thoracic Disease</i> , 2016, 8, E200-E203.	1.4	9
7	Management of large mediastinal masses: surgical and anesthesiological considerations. <i>Journal of Thoracic Disease</i> , 2016, 8, E175-E184.	1.4	58
8	Pre- and postoperative care for stage III NSCLC: Which quality of care indicators are evidence-based?. <i>Lung Cancer</i> , 2016, 101, 120-128.	2.0	8
9	Peri- and postoperative management of stage III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?. <i>Lung Cancer</i> , 2016, 101, 129-136.	2.0	14
10	Optimal surgical management of pulmonary metastases: VATS versus thoracotomy. <i>Respirology</i> , 2016, 21, 188-190.	2.3	17
11	Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up. <i>Annals of Nuclear Medicine</i> , 2016, 30, 362-368.	2.2	9
12	Real-time <i>In Vivo</i> Tissue Characterization with Diffuse Reflectance Spectroscopy during Transthoracic Lung Biopsy: A Clinical Feasibility Study. <i>Clinical Cancer Research</i> , 2016, 22, 357-365.	7.0	53
13	Rebuttal From Dr Li et al. <i>Chest</i> , 2015, 148, 1380-1381.	0.8	0
14	COUNTERPOINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? No. <i>Chest</i> , 2015, 148, 1375-1379.	0.8	4
15	Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 320-324.	2.6	20
16	eComment. Circulating tumour cells caused by surgical manipulation in patients with lung cancer. Is minimally invasive "no-touch" surgery the solution?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 18, 783-783.	1.1	3
17	18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2831-2837.	1.5	27
18	Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1081-1086.	5.0	19

#	ARTICLE	IF	CITATIONS
19	FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World Journal of Radiology, 2014, 6, 392.	1.1	37
20	Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World Journal of Surgical Oncology, 2013, 11, 59.	1.9	12
21	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 547-556.	2.8	18
22	Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy. Lung Cancer, 2013, 80, 165-171.	2.0	63
23	Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 2731-2738.	1.6	82
24	The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2012, 7, 1170-1178.	1.1	119
25	Microscopic Disease Extension in Three Dimensions for Non-Small-Cell Lung Cancer: Development of a Prediction Model Using Pathology-Validated Positron Emission Tomography and Computed Tomography Features. International Journal of Radiation Oncology Biology Physics, 2012, 82, 448-456.	0.8	69
26	Diffuse Reflectance Spectroscopy: A New Guidance Tool for Improvement of Biopsy Procedures in Lung Malignancies. Clinical Lung Cancer, 2012, 13, 424-431.	2.6	48
27	A clinical audit in a multidisciplinary care path for thoracic surgery: An instrument for continuous quality improvement. Lung Cancer, 2012, 78, 270-275.	2.0	34
28	Local treatment of pulmonary metastases: from open resection to minimally invasive approach? Less morbidity, comparable local control. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 2312-2321.	2.4	9
29	Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus. Radiotherapy and Oncology, 2011, 101, 278-283.	0.6	15
30	Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 2011, 117, 3781-3787.	4.1	21
31	Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1939-1948.	1.1	25
32	Is ¹⁸ F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?. Journal of Nuclear Medicine, 2010, 51, 1344-1348.	5.0	80
33	Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. Lung Cancer, 2010, 68, 222-227.	2.0	24
34	EGFR-TKI Treatment and Surgical Resection for Oligometastatic NSCLC?. Onkologie, 2009, 32, 627-628.	0.8	0
35	Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head and Neck, 2009, 31, 220-226.	2.0	22
36	Is Pneumonectomy Justified in Patients With Locally Advanced NSCLC and Persistent N2 Disease After Induction Chemotherapy?. Annals of Thoracic Surgery, 2009, 87, 990-991.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 741-746.	1.4	38
38	Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1226-1230.	1.1	11
39	The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 441-451.	2.0	18
40	Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 6259-6263.	7.0	26
41	Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas. <i>Journal of Clinical Oncology</i> , 2008, 26, 5113-5118.	1.6	53
42	Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4205-4207.	1.6	32
43	Necrotizing pneumonitis caused by postoperative pulmonary torsion. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2008, 7, 144-145.	1.1	20
44	Introduction of lymphangiography and percutaneous embolization of the thoracic duct in a stepwise approach to the management of chylous fistulas. <i>Head and Neck</i> , 2007, 29, 1017-1023.	2.0	36
45	Feasibility of Pathology-Related Lung Imaging for Accurate Target Definition of Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 267-275.	0.8	85
46	Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?. <i>Clinical Cancer Research</i> , 2005, 11, 6608-6614.	7.0	87
47	Transcutaneous Oximetry, Laser Doppler Fluxmetry, and Capillary Microscopy: Variability in Patients with Advanced Atherosclerotic Disease of the Lower Extremity. <i>Vascular Surgery</i> , 2000, 34, 231-243.	0.3	1
48	Spinal-cord stimulation in critical limb ischaemia: a randomised trial. <i>Lancet</i> , The, 1999, 353, 1040-1044.	13.7	174